ArticleInternational urology and nephrology2026
Evaluation of prostate artery embolization for benign prostatic hyperplasia.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the efficacy and safety of prostate artery embolization (PAE) clinically and radiologically in patients with benign prostatic hyperplasia (BPH) under the consideration of several parameters. MATERIALS AND
methodsThis retrospective single-center study included 133 male patients (mean age: 66.8 ± 8 years) with lower urinary tract symptoms (LUTS) due to BPH that underwent PAE. Outcome parameters and clinical questionnaires allowed a comparison of pre-interventional and post-procedural status of quality of life (QoL), international prostate symptom score (IPSS), international index of erectile function (IIEF) and prostate volume. In addition, this study incorporates the psoas muscle index (PMI) to assess its impact on the outcome of the patients. Technical success and complications were also evaluated.
resultsTechnical success was achieved in all cases. All complications were minor and occurred at a rate of 4.5% (6/133). The average follow-up interval following PAE was 17.5 ± 10.9 months. After PAE, the mean prostate volume significantly reduced from 96 ± 26.8 cm
conclusionOur findings suggest that PAE results in a significant improvement in the maintenance of sexual ability among patients suffering from BPH. Moreover, patients with higher muscle mass, indicated by the PMI, have better clinical outcomes.
Indexed as
Identifiers
42801448What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.